Skip to content

Contact +44 (0) 20 7060 7474 email us

Prescription Drugs

Global Antivirals Market Analysis & Forecasts 2008-2023

 

Publication Date September 2008
Publisher Visiongain
Product Type Report
Pages 145
ISBN Number not applicable
Product Code VIS00082

Price

£1,499.00
approximately: $2,296 | €1,670

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Investors are turning their attention to antiviral drug discovery because there is a renewed recognition of the promising opportunities in this $20bn market

  • Twenty years from the inception of focused antiviral drug research, there are 8 blockbuster drugs currently on the market
  • Its double-digit growth makes it a standout segment within the general anti-infective therapeutic class
  • You should be maximizing your opportunities in this market
  • The opportunities for success are there now, you should capitalize on them immediately.

    • The key driver of the market is the rapid development of resistance to existing therapies by the evolving viruses

  • The constant need to update the pipeline fuels your investigative and commercial interest in this market - so you must act on this today
  • This report - Global Antivirals Market, 2008-2023 - analyses the global antiviral market comprehensively, outlining where you should aim your future developments to guarantee success
  • The analyses tackle different aspects of the market, including the leading therapeutic classes, leading antiviral products, key industrial players as partners and financial prospects and opportunities
  • The report also delivers in-depth predictions concerning how the market will develop from present until 2023.

    • Global Antivirals Market, 2008-2023 examines the market for antivirals critically, through comprehensive primary and secondary research

  • In addition to consultation with experts in the industry, this research involved a detailed study of policy documents, industrial reports and relevant news
  • Essentially, visiongain also applied unique in-house techniques such as our developed financial forecasting, SWOT analyses and qualitative projections which are unavailable elsewhere
  • The result is a comprehensive market-focused study with detailed financial analyses and uniquely informed opinion on the future of the antivirals market.

    • In particular, our new Global Antivirals Market 2008-2023 report concentrates on the following essential aspects of that market:

  • Antiviral drugs assessment and opportunities
  • Key industrial players in the global antivirals market
  • Forecasts of global antivirals market from 2008-2023, including in-house developed forecasts of the leading therapeutic agents
  • Forecasts for the antiviral therapies in the seven leading developed pharmaceutical country markets and two leading developing markets
  • Drivers and opportunities in the global antivirals market
  • Restraints and threats in the global antivirals market
  • Key opinion from relevant experts - full interview transcripts are included with the report (unavailable anywhere else)
  • Coverage of pipeline developments in the antivirals market, with discussion of trends from the present onwards

    • Why you should buy this report:

  • To receive a comprehensive analysis of the prospects for the antivirals industry from 2008-2023, including sales forecasts, major growth areas and most exciting pipeline developments
  • To discover predicted revenues, growth rates and other key metrics in the global antivirals market from 2008-2023, with leading brands and principal market segments covered
  • To determine the forces that influence the global antivirals market:
  • Drivers and restraints on that market
  • Competition
  • Strengths, weaknesses, opportunities and threats
  • To find out where the global antivirals market is heading from 2008 onwards - both technologically and commercially

    • The information contained in this report is not available in any other source and is essential reading for you and your colleagues

  • By ordering and reading this report you can gain market advantage on your competitors today.

    • When aligned with your in-house findings we are confident you will continue to succeed over the next 15 years.

    Contents

    • 1 Executive Summary
      • 1.1 Aims of This Report
      • 1.2 A Brief Overview of the Chapters
    • 2 Introduction
      • 2.1 What is a Virus?
      • 2.2 History of Virology
        • 2.2.1 Origin of Viruses
        • 2.2.2 Historical Developments in Virology
      • 2.3 Classification of Viruses
        • 2.3.1 DNA Viruses
        • 2.3.2 RNA Viruses
        • 2.3.3 Reverse Transcribing Viruses
      • 2.4 Introduction to Viral Infections
        • 2.4.1 Viral Life Cycle
        • 2.4.2 Intrinsic Human Defences against Virus
      • 2.5 How Do Antivirals Work?
        • 2.5.1 Approach to Life Cycle Management
          • 2.5.1.1 Before Cell Entry
          • 2.5.1.2 During Viral Synthesis
          • 2.5.1.3 Release Phase
        • 2.5.2 Immune System Modulating
      • 2.6 Antivirals Battle Highly Mutational Viral Genomes
      • 2.7 The World Anti-Infective Market
        • 2.7.1 Market Shares
    • 3 The Global Market for Anti-Viral Drugs, 2008-2023
      • 3.1 The Global Anti-Viral Market Generated High Revenues in 2007
        • 3.1.1 Leading Segments in the Global Anti-Viral Market
        • 3.1.2 Reverse Transcriptase Inhibitors, Immunoglobulin, Protease Inhibitors
          • and Vaccine Segments
      • 3.2 Global Anti-Viral Market Forecast, 2008-2023
      • 3.3 Global Anti-Viral Market by Disease Area, 2008-2023
      • 3.4 The Rise of the Hepatitis Segment from 2008 to 2013
      • 3.5 The HIV Market Impeded by Patent Issues
        • 3.5.1 Anti-HIV Agents Facing Looming Patent Expiries
        • 3.5.2 Controversy Surrounding Patent Rights
      • 3.6 The Influenza Segment Growth is Hampered by Conflicts
      • 3.7 The Global Anti-Viral Market Will Undergo Shift
      • 3.8 Leading Anti-Viral Brands and Forecast, 2008-2023
        • 3.8.1 Will Tamiflu Retain its Leadership Position?
        • 3.8.2 Combination Therapy Deemed Most Effective
        • 3.8.3 Pegasys-Ribavirin Combination Therapy
        • 3.8.4 Atripla - the Way Forward?
      • 3.9 The Anti-Viral Market and Investment Activities
    • 4 Factors Affecting the World Anti-Viral Market, 2008-2023
      • 4.1 SWOT Analysis of the Anti-Viral Market
      • 4.2 There is Much Reason for Optimism in the Anti-Viral Market
        • 4.2.1 Drug Resistance is a Major Concern, but Stimulates Research Activity
        • 4.2.2 Chronic Indications Ensure Long-Term Demand for Antivirals
        • 4.2.3 Outbreaks of Viral Infections Give Rise to Major Global Public Health
          • Crises
        • 4.2.4 Low Diagnostic Rate Means that the Majority of Patients Are Unaware of
          • Their Infections
      • 4.3 Current Antiviral Treatments Marred by High Toxicity and Low Patient
        • Compliance
      • 4.4 The Threat of Bio-generic Penetration
        • 4.4.1 Looming Patent Expiry Threatens Some Leading Brands
        • 4.4.2 Does the Pipeline Have Enough Potential to Replace the Aging Brands?
      • 4.5 Variability of Novel Targets and Mechanisms
      • 4.6 Investment and Commercial Obstacles
        • 4.6.1 Low Prevalence of Treatable Viral Diseases
        • 4.6.2 Low Profitability from the Developing Countries
      • 4.7 The Market Needs to Overcome Economic and Political Obstacles to Gain
        • Access to Patients in Need
        • 4.7.1 Will the Expanding Patient Population Drive Market Growth? A Case
          • Study of the HIV Market
        • 4.7.2 Expensiveness of Antiviral Treatments Forces Market Exclusivity and
          • Limits Market Growth
        • 4.7.3 Conjoint Effort from the Public and Private Domains to Achieve Greater
          • Accessibility is a Positive Step Forward
      • 4.8 How Will the Manufacturers Answer to Public Demands for Enhancing
        • Treatment Availability?
        • 4.8.1 Production Rate Unable to Meet Demands
        • 4.8.2 The Controversy Towards Overriding Patent Rights
      • 4.9 Are Vaccines Friends or Foes to the Antiviral Market?
    • 5 Leading Companies in the Antiviral Market, 2008-2023
      • 5.1 GSK, Roche, Merck, Gilead Sciences and Bristol-Myers Squibb
      • 5.2 Is GSK's Market Dominance in Jeopardy?
      • 5.3 Roche's Pipeline
      • 5.4 What is Merck's Competitive Edge in the Antiviral Market?
      • 5.5 Gilead Sciences and Bristol-Myers Squibb Carve into the HIV Market
    • 6 Leading Antiviral Brands, Forecasts and Analyses, 2008-2023
      • 6.1 Top 15 Marketed Antivirals of 2007
      • 6.2 Tamiflu
      • 6.3 Gardasil
      • 6.4 Valtrex
      • 6.5 Pegasys
      • 6.6 Truvada
      • 6.7 Varivax
      • 6.8 Synagis
      • 6.9 Reyataz
      • 6.10 Kaletra
      • 6.11 Sustiva
      • 6.12 Atripla
      • 6.13 Combivir
      • 6.14 Peg-Intron
      • 6.15 Epzicom
      • 6.16 Viread
    • 7 Antivirals in the Leading Pharmaceutical Markets, Forecasts and Analysis,
    • 2008-2023
      • 7.1 Sales of Antivirals in the Leading Pharmaceutical Markets in 2007
      • 7.2 Market Performance of Antivirals in the Leading Pharmaceutical Nations,
    • 2008-2023
      • 7.3 Will the US Retain Dominance?
      • 7.4 Other Industrialised Countries to Undergo Steady Growth
      • 7.5 How Will the Leading Developing Countries Fare in the Global Antivirals
        • Market?
    • 8 Promising Anti-Viral Technologies and Pipeline Developments
      • 8.1 HIV Pipeline Development
        • 8.1.1 Research Direction
        • 8.1.2 Viral Enzymes as Targets
        • 8.1.3 NNRTI
          • 8.1.3.1 Intelence
          • 8.1.3.2 Rilpivirine
        • 8.1.4 NRTI
          • 8.1.4.1 Apricitabine
        • 8.1.5 Host Proteins as Targets
        • 8.1.6 Viral-Entry Inhibitors: Attachment, Entry and Fusion Inhibitors
          • 8.1.6.1 Selzentry/Celsentri
          • 8.1.6.2 Vicriviroc
        • 8.1.7 Integrase Inhibitors
          • 8.1.7.1 Isentress
          • 8.1.7.2 Elvitegravir
        • 8.1.8 Maturation Inhibitors
          • 8.1.8.1 Bevirimat
      • 8.2 Hepatitis Pipeline Development
        • 8.2.1 Research Direction
        • 8.2.2 Interferons
          • 8.2.2.1 Albuferon
        • 8.2.3 NS3 Protease Inhibitors
          • 8.2.3.1 Telaprevir
          • 8.2.3.2 Boceprevir
        • 8.2.4 Polymerase Inhibitors
          • 8.2.4.1 R7128
      • 8.3 Novel Technologies Head the Next Wave of Anti-Viral Drug Exploration
        • 8.3.1 Could Monoclonal Antibodies Surpass the Dominant Small-Molecules?
        • 8.3.2 RNA Interference Technology Raises Investment Interest
    • 9 Interviews with Relevant Experts - Discussion of Current and Future Trends
      • 9.1 Interview 1: Professor Erik De Clercq, Emeritus Professor, Rega
        • Institute for Medical Research, K.U. Leuven, Belgium.
        • 9.1.1 Promising Sub-Markets
        • 9.1.2 Market Drivers and Restraints
        • 9.1.3 Promising R&D Programmes
        • 9.1.4 Market Direction
      • 9.2 Interview 2: Dr. Michael Kinch, VP, Research and Development, Functional
        • Genetics, Maryland, USA
        • 9.2.1 Promising Sub-Markets
        • 9.2.2 Market Drivers and Restraints
        • 9.2.3 Arguments for Host-Oriented Therapeutic Approach
        • 9.2.4 Biologicals Versus Small Molecules
    • 10 Conclusions
      • 10.1 Excitement Surrounds the Antivirals Market
      • 10.2 The Next Market Leader
      • 10.3 Hepatitis Segment Drives Innovative Antiviral Research
      • 10.4 Pipeline Development
      • 10.5 The Future of Antivirals
    • List of Tables
      • Table 2.1, Historical Developments in Virology
      • Table 2.2, Categorisation of Clinically Significant Viruses
      • Table 2.3, The World Anti-Infective Market, Sales ($bn), 12 months to Q1 2008
      • Table 3.1, Antiviral Therapies Blockbusters, Sales ($m) and Market Share (%), 2007
      • Table 3.2, Global Anti-Viral Market, Sales ($bn) and Growth (%), 2006-2013, 2018, 2023
      • Table 3.3, Global Antiviral Market Breakdown by Disease Area, 2006 and 2007
      • Table 3.4, Global Anti-Viral Market by Disease Area, Sales ($bn) and Annual Growth (%), 2006-2013
      • Table 3.5, Market Performance of the Hepatitis Segment, Sales ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2008-2013, 2018 and 2023
      • Table 3.6, Marketed Antiviral Therapies for HIV/AIDS, Sales ($m), 2007
      • Table 3.7, Market Performance of the HIV Segment, Sales ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2008-2013, 2018 and 2023
      • Table 3.8, Market Performance of the Influenza Segment, Sales ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2008-2013, 2018 and 2023
      • Table 3.9, Global Anti-Viral Market by Disease Area, CAGR (%) and Market Share (%), 2007, 2013, 2018 and 2023
      • Table 3.10, Top 15 Anti-Viral Brands, Sales ($m) and Growth (%), 2007
      • Table 3.11, Top 15 Anti-Viral Brands, Sales ($m) and Growth (%), 2006-2013
      • Table 4.1, SWOT Analysis of the Antiviral Market, 2008
      • Table 4.2, Antivirals with Recent or Imminent Patent Expiration
      • Table 4.3, Antiviral Patents Approved in the United States
      • Table 5.1, Leading Companies in the Antiviral Market, Sales ($bn), 2007
      • Table 6.1, Sales of Tamiflu ($m), 2006-2013
      • Table 6.2, Sales of Gardasil ($m), 2006-2013
      • Table 6.3, Sales of Valtrex ($m), 2006-2013
      • Table 6.4, Sales of Pegasys ($m), 2006-2013
      • Table 6.5, Sales of Truvada ($m), 2006-2013
      • Table 6.6, Sales of Varivax ($m), 2006-2013
      • Table 6.7, Sales of Synagis ($m), 2006-2013
      • Table 6.8, Sales of Reyataz ($m), 2006-2013
      • Table 6.9, Sales of Kaletra ($m), 2006-2013
      • Table 6.10, Sales of Sustiva ($m), 2006-2013
      • Table 6.11, Sales of Atripla ($m), 2006-2013
      • Table 6.12, Sales of Combivir ($m), 2006-2013
      • Table 6.13, Sales of Peg-Intron ($m), 2006-2013
      • Table 6.14, Sales of Epzicom ($m), 2006-2013
      • Table 6.15, Sales of Viread ($m), 2006-2013
      • Table 7.1, Antivirals in the Leading Pharmaceutical Markets, Sales ($), Market Share (%) and Annual Growth (%), 2007
      • Table 7.2, Antivirals in the Leading Pharmaceutical Markets, Sales ($m), 2007-2013, 2018, 2023
      • Table 7.3, Antivirals in the Leading Pharmaceutical Markets, Market Share (%) and CAGR (%), 2007 and 2013
      • Table 8.1, HIV Life Cycle and Potential Targets for Antiretrovirals
      • Table 8.2, Selected Viral Enzymes Inhibitors in Late Clinical Development
      • Table 8.3, Selected Entry Inhibitors in Late Clinical Development
      • Table 8.4, Selected Integrase Inhibitors in Late Clinical Development
      • Table 8.5, Selected Interferons in Late Stage Development
      • Table 8.6, Selected NS3 Protease Inhibitors in Late Clinical Development
      • Table 8.7, Selected Polymerase Inhibitors in Late Clinical Development
      • Table 8.8, Commercial Development of Antiviral mAbs
      • Table 10.1, Global Anti-Viral Market, Sales ($bn) and Growth (%), 2006-2013, 2018, 2023
      • Table 10.2, Antiviral Therapies Blockbusters, Sales ($m) and Market Share (%), 2007
    • List of Figures
      • Figure 2.1, Basic Structures of the Influenza Virus
      • Figure 2.2, Life Cycle of a Typical RNA Virus
      • Figure 2.3, The World Anti-Infective Market, Sales ($bn), 12 months to Q1 2008
      • Figure 2.4, The World Anti-Infective Market, Market Share (%), 12 months to Q1 2008
      • Figure 3.1, Leading Disease Areas in the Anti-Viral Market, Sales ($bn), 2007
      • Figure 3.2, Leading Drug Classes in the Anti-Viral Market, Sales 2007 ($bn)
      • Figure 3.3, Global Anti-Viral Market Sales ($m), 2006-2013
      • Figure 3.4, Global Antiviral Market by Disease Area, Market Share (%), 2007
      • Figure 3.5, Global Anti-Viral Market by Disease Area, Sales ($m), 2006-2013
      • Figure 3.6, Global Hepatitis Market, Sales ($bn), 2006-2023
      • Figure 3.7, Global HIV Market, Sales ($bn), 2006-2023
      • Figure 3.8, Global Influenza Market, Sales ($bn), 2006-2023
      • Figure 3.9, Global Antiviral Market by Disease Area, Market Share (%), 2013
      • Figure 3.10, Market Share of the Leading Anti-Viral Drugs (%), 2007
      • Figure 5.1, Leading Companies in the Antiviral Market, Market Share (%), 2007
      • Figure 6.1, Top 15 Marketed Antiviral Therapies, Sales ($m), 2007
      • Figure 6.2, Top 15 Marketed Antiviral Therapies, Annual Growth (%), 2007
      • Figure 6.3, Sales of Tamiflu ($m), 2006-2023
      • Figure 6.4, Sales of Gardasil ($m), 2006-2023
      • Figure 6.5, Sales of Valtrex ($m), 2006-2023
      • Figure 6.6, Sales of Pegasys ($m), 2006-2023
      • Figure 6.7, Sales of Truvada ($m), 2006-2023
      • Figure 6.8, Sales of Varivax ($m), 2006-2023
      • Figure 6.9, Sales of Synagis ($m), 2006-2023
      • Figure 6.10, Sales of Reyataz ($m), 2006-2023
      • Figure 6.11, Sales of Kaletra ($m), 2006-2023
      • Figure 6.12, Sales of Sustiva ($m), 2006-2023
      • Figure 6.13, Sales of Atripla ($m), 2006-2023
      • Figure 6.14, Sales of Combivir ($m), 2006-2023
      • Figure 6.15, Sales of Peg-Intron ($m), 2006-2023
      • Figure 6.16, Sales of Epzicom ($m), 2006-2023
      • Figure 6.17, Sales of Viread ($m), 2006-2023
      • Figure 7.1, Antivirals in the Leading Pharmaceutical Markets, Sales ($m), 2007
      • Figure 7.2, Antivirals in the Leading Pharmaceutical Markets, Market Share (%), 2007
      • Figure 7.3, Antivirals in the US Market, Sales ($m), 2008-2013
      • Figure 7.4, Antivirals in Other Leading Industrialised Countries, Sales ($m), 2008-2013
      • Figure 7.5, Antivirals in China and India, Sales ($m), 2008-2013
    • Companies listed:
      • Abbott
      • AIDS Drug Assistance Programme
      • Alnylam Pharmaceutical
      • AnorMed
      • AstraZeneca
      • Aurobindo
      • Avexa
      • Benitec
      • Bill and Melinda gates Foundation
      • Biolex Therapeutics
      • Boehringer Ingelheim
      • Bristol-Myers Squibb (BMS)
      • Cipla
      • Genentech
      • Genzyme
      • Gilead Sciences
      • Glaxo Wellcome
      • GlaxoSmithKline (GSK)
      • Hoffmann-La Roche
      • Human Genome Sciences
      • Incyte
      • Intarcia
      • International AIDS Vaccine Initiative (NIAID)
      • Japan Tobacco
      • Johnson and Johnson
      • Jointed United Nations Programme on HIV/AIDS (UNAIDS)
      • MedImmune
      • Medivir
      • Merck
      • Mitsubishi
      • Monogram Biosciences
      • Novartis
      • OctoPlus
      • Panacos
      • Pfizer
      • Pharmaplaz
      • Pharmasset Inc
      • Progenics
      • Rega Institute for Medical Research
      • Samaritan
      • Schering-Plough
      • Tacere Therapeutics
      • Teijin Pharma
      • Tibotec
      • Tibotec-Virco
      • Trimeris
      • US Centers for Disease Control and Prevention (CDC)
      • US President's Emergency Plan for AIDS Relief (PEPFAR)
      • Vertex Pharmaceuticals
      • ViroChem Pharma
      • World Bank
      • World Health Organization (WHO)